News Sharing
For sharing news, please enter the email address of you and the receiver, then press SEND button.*Mandatory Fields
Receiver*
Enter email addresses, separated by semicolon (;). E.g. a@a.com;b@b.com
Your email address*
 Content Sharing
<Research>Citi: US Proposal to Ban Adoption of CN Clinical Trial Data Has Low Possibility to Pass into Law
According to Endpoints News, on last Thursday (30 April), the US House Appropriations Committee approved a draft report urging the US Food and Drug Administration (FDA) to prohibit...
Reset
Send
The window will close in 5 seconds
<Research>Citi: US Proposal to Ban Adoption of CN Clinical Trial Data Has Low Possibility to Pass into Law
Close
Recommend
58
Positive
113
Negative
44
 
SHORT SELL
 
STOCK INFO
aacat by AASTOCKS
Open a new trading account to get 1 Intel/Selected Gold ETF share!

According to Endpoints News, on last Thursday (30 April), the US House Appropriations Committee approved a draft report urging the US Food and Drug Administration (FDA) to prohibit the use of clinical trial data generated in China in future drug development applications, including Investigational New Drug (IND) applications, Citi Research issued a research report saying.

The broker believed that the likelihood of the draft ultimately being passed into law is low as China's more efficient clinical trial environment is also helping global multinational pharmaceutical companies refill their drug development pipelines with high quality and speed; commercialization of 'Chinese molecules' in the US ultimately needs to conduct late-stage trials in the US, with substantial enrollment of US patients, and approvals are likewise based on US data.

Related NewsUOB Kay Hian Adds COWELL, NTES-S to Buy List, Recommends Buying on Pullbacks
Citi Research will host an expert call on the topic tonight (4th) Hong Kong time and will release more details soon.

Auto-translated by AI
View Original Text
This article was automatically translated by AI, the original language version should be considered the authoritative version. AASTOCKS.com Limited does not guarantee its accuracy or completeness and accepts no liability for any damages or losses arising from the use of this translation.

AASTOCKS Financial News
Copyright(C) AASTOCKS.com Limited 2000. All rights reserved.
Disclaimer: AASTOCKS.com Ltd, HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the Information provided but do not guarantee its accuracy or reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.